Entrada ( TRDA ) Q2 Revenue Drops 98%
Entrada Therapeutics ( NASDAQ:TRDA ) , a biotechnology company developing intracellular therapies for rare neuromuscular diseases, reported second quarter 2025 financial results on August 6, 2025. The main news from the release was a sharp drop in revenue from collaboration activities and a ...
Entrada Therapeutics, Inc. ( TRDA ) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - Entrada Therapeutics ( NASDAQ:TRDA ) , Biogen ( NASDAQ:BIIB )
BOSTON, June 03, 2025 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Entrada Therapeutics ( NASDAQ:TRDA )
BOSTON, June 02, 2025 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA today announced that the Company granted an aggregate of 23,820 restricted stock units ( "RSUs" ) to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan ( the "Inducement Plan" ) , ...
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
Entrada Therapeutics announces inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
Entrada Therapeutics, Inc. ( TRDA ) Reports Q1 Loss, Tops Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 46.15% and 111.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. ( ETON ) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Entrada Therapeutics, Inc. ( TRDA ) to Report a Decline in Earnings: What to Look Out for
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx ( RARE ) Soars 9.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Entrada Therapeutics, Inc. ( TRDA ) Surpasses Q4 Earnings and Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - Entrada Therapeutics ( NASDAQ:TRDA )
- Received FDA authorization to initiate ELEVATE-44-102 in the U.S. - - Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. - - Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU -
Vir Biotechnology, Inc. ( VIR ) Reports Q4 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of 10.59% and 15.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy - Entrada Therapeutics ( NASDAQ:TRDA )
FDA lifted the clinical hold on Entrada's ENTR-601-44, allowing the Phase 1b ELEVATE-44-102 study for Duchenne muscular dystrophy to proceed The trial will assess safety, target engagement and dosing in 32 ambulatory and non-ambulatory patients amenable to exon 44 skipping.
Here's Why Encompass Health is a Smart Addition to Your Portfolio
EHC is well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, frequent expansion initiatives and solid cash reserves.
Best Momentum Stocks to Buy for December 30th
CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.
New Strong Buy Stocks for December 30th
CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Entrada Therapeutics ( NASDAQ:TRDA )
BOSTON, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible.
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. ( Nasdaq: TRDA ) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible.
Entrada Therapeutics, Inc. ( TRDA ) Reports Q3 Loss, Tops Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 47.76% and 20.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. ( ARVN ) Reports Q3 Loss, Tops Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of 22.73% and 45.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - Entrada Therapeutics ( NASDAQ:TRDA )
- Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial -
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
- Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial -
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - Entrada Therapeutics ( NASDAQ:TRDA )
BOSTON, Sept. 24, 2024 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle ( EEV™ ) -therapeutics as a new class of medicines.
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
BOSTON, Sept. 24, 2024 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. ( Nasdaq: TRDA ) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle ( EEV™ ) -therapeutics as a new class of medicines.
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS ( DREAMS ) Grant Program
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program ...
AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer - AstraZeneca ( NASDAQ:AZN ) , Immatics ( NASDAQ:IMTX )
AstraZeneca AZN announced that the combination therapy of its PD-L1 inhibitor, Imfinzi ( durvalumab ) , and PARP inhibitor, Lynparza ( olaparib ) , has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.
AstraZeneca ( AZN ) Imfinzi Combo Gets EU Nod for Uterine Cancer
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
Evotec Rises 12% on $75M Milestone Payment From BMY - Bristol-Myers Squibb ( NYSE:BMY ) , Evotec ( NASDAQ:EVO )
Evotec EVO achieved substantial progress in its strategic partnership with Bristol Myers Squibb BMY relating to building a molecular glue-based pipeline. This triggered a performance-based and program-based payment of $75 million payable to the company.
Lexicon ( LXRX ) to Reprioritize Portfolio, Slash Jobs, Stock Up
Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.
Ascendis ( ASND ) Up on FDA Nod for Hormone Therapy Yorvipath
The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.
Evotec ( EVO ) Rises 12% on $75M Milestone Payment From BMY
A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.
Syros ( SYRS ) Falls 62% on Phase II Leukemia Study Termination
Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
CLEVELAND, Aug. 14, 2024 ( GLOBE NEWSWIRE ) -- Abeona Therapeutics Inc. ( Nasdaq: ABEO ) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors.
Here's Why You Should Invest in BioMarin ( BMRN ) Stock Now
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
Exelixis ( EXEL ) Gains 14.9% in a Week on Strong Q2 Results
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Entrada Therapeutics, Inc. ( TRDA ) Tops Q2 Earnings and Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 138.46% and 72.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion's ( ESPR ) Q2 Loss Narrows, Revenues Soar Year Over Year
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.
Merck ( MRK ) to Buy Curon's Bispecific Antibody Drug for $1.3B
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
Pacira ( PCRX ) Plummets as US Court Deems Exparel Patent Invalid
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Avidity Biosciences, Inc. ( RNA ) Reports Q2 Loss, Misses Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of 14.47% and 71.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Novavax Lags on Q2 Earnings & Sales, Cuts '24 Outlook - Fulcrum Therapeutics ( NASDAQ:FULC ) , Novavax ( NASDAQ:NVAX )
Novavax NVAX posted earnings per share of 99 cents in second-quarter 2024, missing the Zacks Consensus Estimate of $1.82. However, earnings rose 71% year over year. Revenues in the quarter amounted to $415.5 million, also missing the Zacks Consensus Estimate of $453.7 million.
Nektar's Q2 Earnings Lag Estimates, Revenues Top - Eli Lilly ( NYSE:LLY ) , Nektar Therapeutics ( NASDAQ:NKTR )
Nektar Therapeutics NKTR incurred a loss per share of 25 cents in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 21 cents.
Insmed ( INSM ) Lags on Q2 Earnings, Tops Sales, Reiterates View
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
Intellia's ( NTLA ) Q2 Earnings & Revenues Fall Shy of Estimates
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Novavax ( NVAX ) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
Nektar's ( NKTR ) Q2 Earnings Lag Estimates, Revenues Top
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Cytokinetics ( CYTK ) Q2 Loss Wider Than Expected, Pipeline in Focus
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Gilead ( GILD ) Q2 Earnings Beat, Annual Profit Guidance Raised
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Iovance ( IOVA ) Q2 Earnings Beat, Stock Up on Upbeat Sales View
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
